FTP-198 / Haisco - LARVOL DELTA

Pharmacokinetics, pharmacodynamics, safety and tolerability of FTP-198, a novel, selective autotaxin inhibitor, in healthy subjects: a phase I randomized placebo-controlled trial. (PubMed, Eur J Pharm Sci) - "Pharmacokinetics, pharmacodynamics, safety and tolerability of FTP-198 support further subsequent clinical development of FTP -198 in IPF patients."

Clinical • Journal • P1 data • PK/PD data • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

Safety, Tolerability and Pharmacokinetics of FTP-198 Tablet in Healthy Chinese Volunteers (clinicaltrials.gov) - P1 | N=31 | Completed | Sponsor: Haisco Pharmaceutical Group Co., Ltd. | Recruiting ➔ Completed

Trial completion

Safety, Tolerability and Pharmacokinetics of FTP-198 in Healthy Australian Volunteers (clinicaltrials.gov) - P1; N=75; Completed; Sponsor: Sichuan Haisco Pharmaceutical Group Co., Ltd; Recruiting ➔ Completed

Clinical • Trial completion

Safety, Tolerability and Pharmacokinetics of FTP-198 Tablet in Healthy Chinese Volunteers (clinicaltrials.gov) - P1; N=30; Recruiting; Sponsor: Haisco Pharmaceutical Group Co., Ltd.

Clinical • New P1 trial

Hasko's innovative drug for idiopathic pulmonary fibrosis approved for clinical trials [Google translation] (Eastmoney.com) - "Haisco An announcement was made that the company's Class 1 innovative drug FTP-198 tablets has been approved for clinical trials and is intended to be used for the treatment of idiopathic pulmonary fibrosis (IPF)....FTP-198 tablets passed the Australian ethics review in January this year. Single/multiple administration, randomized, double-blind , placebo-controlled, and dose-escalation studies will be carried out in healthy people in the first quarter of 2020."

New trial • Non-US regulatory • Idiopathic Pulmonary Fibrosis

[Company] Hisco's innovative drug for idiopathic pulmonary fibrosis FTP-198 tablets was approved to enter clinical trials [Google translation] (Shenzhen Panorama Network) - "Haisco...issued an announcement stating that the company’s innovative drug FTP-198 tablets has obtained the 'Notice of Acceptance' from the National Medical Products Administration, marking that the product can apply for the indication 'Idiopathic Pulmonary Fibrosis' Clinical Trials."

Non-US regulatory • Idiopathic Pulmonary Fibrosis